Breaking bad habits: Targeting MDSCs to alleviate immunosuppression in prostate cancer

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Myeloid-derived suppressor cells (MDSCs) are key players in tumor immune evasion.
• MDSCs represent a challenging therapeutic target in cancer treatment.
• Understanding MDSC accumulation and function is crucial for developing effective cancer therapies.

Purpose of the Study:

• To investigate the role of granulocytic MDSCs in prostate cancer progression.
• To evaluate the therapeutic potential of targeting MDSCs in prostate cancer.
• To assess the feasibility of a STAT3 siRNA-based strategy against MDSCs.

Main Methods:

• Identification and quantification of granulocytic MDSCs in prostate cancer patients.
• In vitro or in vivo experiments to assess the effect of STAT3 siRNA on MDSCs.
• Analysis of T cell activity and arginase-dependent suppression.

Main Results:

• Granulocytic MDSCs were found to accumulate during prostate cancer progression.
• A STAT3 siRNA-based strategy was demonstrated to be feasible for targeting MDSCs.
• This approach showed potential in alleviating arginase-dependent suppression of T cell activity.

Conclusions:

• Granulocytic MDSCs are implicated in prostate cancer progression.
• Targeting MDSCs with STAT3 siRNA offers a promising therapeutic strategy.
• This approach may help overcome tumor-induced immune suppression in prostate cancer.